Statin Intensity and Coronary Allograft Vasculopathy After Heart Transplantation

• Status: Not yet recruiting
• Trial end date: 2026-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigator's propose to conduct an open-label randomized controlled trial to determine if higher intensity statin (HS) can reduce CAV in comparison to lower intensity statin (LS) after HT. All consecutive patients that meet eligibility criteria will be approached for participation. After heart transplantation, participants (n=70) will be randomized in a 1:1 manner to either HS (Atorvastatin 40 mg daily) or LS (Pravastatin 40 mg daily). Study participation will be for 2 years from the time of randomization.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Montefiore Medical Center
• Treatments: Atorvastatin

Criteria

Inclusion Criteria:

• Waitlisted for Heart Transplantation

• Capacity to provide informed consent

Exclusion Criteria:

• History of statin allergy or intolerance

• Hepatic dysfunction

• Redo Heart Transplant

• Awaiting combined heart and liver transplantation